Medicamen Biotech (MBL) has planned a partial shutdown of its plant at Bhiwadi (Rajasthan) for 4 to 6 weeks. During this upgradation the production/activities shall remain partially suspended. The upgradation would not only enable MBL to prepare for regulated market but also provide next level of growth in terms of good volume business with better margins.
Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.